Spyre Therapeutics (SYRE) Q3 2026 earnings summary

Executive summary

• Q3 operating expenses rose 86% YoY to $105.7M and net loss widened to $96.1M from $11.2M, reflecting expanded clinical, manufacturing and compensation costs and a less favorable CVR revaluation.

• SPY001, SPY002 and SPY003 met primary endpoints in SKYLINE UC Part A; SPY072 will not advance in rheumatic diseases after mixed-to-negative results.

• October financing and post-quarter ATM sales support expected runway into H2 2029; SKYLINE combination enrollment is ahead of schedule.

Financial highlights

• Q3 R&D was $89.2M vs. $45.2M YoY; G&A was $16.6M vs. $11.6M, and operating expenses totaled $105.7M vs. $56.9M.

• Q3 net loss was $96.1M vs. $11.2M; common-stock loss per share was $0.94 vs. $0.15. Net cash used in operating activities was $77.5M.

• Q3 total other income was $9.6M vs. $45.7M YoY, with the prior-year comparison affected by a CVR-liability fair-value change.

• 9M R&D was $215.1M vs. $127.0M, G&A was $47.9M vs. $35.4M, and net loss was $201.3M vs. $92.7M.

• 9M results included a $70.0M gain on the pegzilarginase asset sale vs. $10.0M in 2025; common-stock loss per share was $2.04 vs. $1.24.

Outlook and guidance

• Existing liquidity, October 2026 offering proceeds and post-quarter ATM sales are expected to fund planned operating expenses and capital needs into H2 2029; estimates depend on assumptions that may prove inaccurate.

• SKYLINE Part B induction results for three IBD combination programs are expected in Q3 2027; enrollment is ahead of schedule and the target enrollment has increased.

• SKYLIGHT Week 16 topline results are planned for late 2027 or early 2028; potential SPY072 HS monotherapy pivotal studies are planned for 2027.

• Operating losses are expected to increase with clinical development, manufacturing and pipeline investment; additional financing will be needed in the future.